|
1
|
Kaul K, Hodgkinson A, Tarr JM, Kohner EM
and Chibber R: Is inflammation a common retinal-renal-nerve
pathogenic link in diabetes? Curr Diabetes Rev. 6:294–303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Busch M, Franke S, Rüster C and Wolf G:
Advanced glycation end-products and the kidney. Eur J Clin Invest.
40:742–755. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamagishi S: Role of advanced glycation
end products (AGEs) and receptor for AGEs (RAGE) in vascular damage
in diabetes. Exp Gerontol. 46:217–224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Navarro-González JF and Mora-Fernández C:
Inflammatory pathways. Contrib Nephrol. 170:113–123. 2011.
|
|
5
|
Yamagishi S and Imaizumi T: Diabetic
vascular complications: pathophysiology, biochemical basis and
potential therapeutic strategy. Curr Pharm Des. 11:2279–2299. 2005.
View Article : Google Scholar
|
|
6
|
van Dijk C and Berl T: Pathogenesis of
diabetic nephropathy. Rev Endocr Metab Disord. 5:237–248. 2004.
|
|
7
|
Furuta T, Saito T, Ootaka T, Soma J, Obara
K, Abe K and Yoshinaga K: The role of macrophages in diabetic
glomerulosclerosis. Am J Kidney Dis. 21:480–485. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nguyen D, Ping F, Mu W, Hill P, Atkins RC
and Chadban SJ: Macrophage accumulation in human progressive
diabetic nephropathy. Nephrology (Carlton). 11:226–231. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yonemoto S, Machiguchi T, Nomura K,
Minakata T, Nanno M and Yoshida H: Correlations of tissue
macrophages and cytoskeletal protein expression with renal fibrosis
in patients with diabetes mellitus. Clin Exp Nephrol. 10:186–192.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chow F, Ozols E, Nikolic-Paterson DJ,
Atkins RC and Tesch GH: Macrophages in mouse type 2 diabetic
nephropathy: correlation with diabetic state and progressive renal
injury. Kidney Int. 65:116–128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Braunersreuther V, Mach F and Steffens S:
The specific role of chemokines in atherosclerosis. Thromb Haemost.
97:714–721. 2007.PubMed/NCBI
|
|
12
|
Bazan JF, Bacon KB, Hardiman G, Wang W,
Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of
membrane-bound chemokine with a CX3C motif. Nature. 385:640–644.
1997. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong BW, Wong D and McManus BM:
Characterization of fractalkine (CX3CL1) and CX3CR1 in human
coronary arteries with native atherosclerosis, diabetes mellitus,
and transplant vascular disease. Cardiovasc Pathol. 11:332–338.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kikuchi Y, Ikee R, Hemmi N, Hyodo N,
Saigusa T, Namikoshi T, Yamada M, Suzuki S and Miura S: Fractalkine
and its receptor, CX3CR1, upregulation in streptozotocin-induced
diabetic kidneys. Nephron Exp Nephrol. 97:e17–e25. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lesnik P, Haskell CA and Charo IF:
Decreased atherosclerosis in CX3CR1−/− mice reveals a
role for fractalkine in atherogenesis. J Clin Invest. 111:333–340.
2003.PubMed/NCBI
|
|
16
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
structure, function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Corbel M, Belleguic C, Boichot E and
Lagente V: Involvement of gelatinases (MMP-2 and MMP-9) in the
development of airway inflammation and pulmonary fibrosis. Cell
Biol Toxicol. 18:51–61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
John A and Tuszynski G: The role of matrix
metalloproteinases in tumor angiogenesis and tumor metastasis.
Pathol Oncol Res. 7:14–23. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brosius FC III: New insights into the
mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev
Endocr Metab Disord. 9:245–254. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alsaad KO and Herzenberg AM:
Distinguishing diabetic nephropathy from other causes of
glomerulosclerosis: an update. J Clin Pathol. 60:18–26. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mason RM and Wahab NA: Extracellular
matrix metabolism in diabetic nephropathy. J Am Soc Nephrol.
14:1358–1373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagase H and Woessner JF Jr: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
|
|
23
|
Sun Z, Liu N and Liu B: The preparation
and application of antiserum against advanced glycated end
products. Chin J Lab Med. 5:293–295. 1999.(In Chinese).
|
|
24
|
Zilin S, Naifeng L, Bicheng L and Jiping
W: The determination of AGE-peptides by flow injection assay, a
practical marker of diabetic nephropathy. Clin Chim Acta.
313:69–75. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kenig S, Alonso MB, Mueller MM and Lah TT:
Glioblastoma and endothelial cells cross-talk, mediated by SDF-1,
enhances tumour invasion and endothelial proliferation by
increasing expression of cathepsins B, S, and MMP-9. Cancer Lett.
289:53–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang CH, Tan TW, Fu WM and Yang RS:
Involvement of matrix metalloproteinase-9 in stromal cell-derived
factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis.
29:35–43. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vitale S, Schmid-Alliana A, Breuil V,
Pomeranz M, Millet MA, Rossi B and Schmid-Antomarchi H: Soluble
fractalkine prevents monocyte chemoattractant protein-1-induced
monocyte migration via inhibition of stress-activated protein
kinase 2/p38 and matrix metalloproteinase activities. J Immunol.
172:585–592. 2004. View Article : Google Scholar
|
|
28
|
Klier CM, Nelson EL, Cohen CD, Horuk R,
Schlöndorff D and Nelson PJ: Chemokine-induced secretion of
gelatinase B in primary human monocytes. Biol Chem. 382:1405–1410.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cross AK and Woodroofe MN: Chemokine
modulation of matrix metalloproteinase and TIMP production in adult
rat brain microglia and a human microglial cell line in vitro.
Glia. 28:183–189. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Madri JA and Graesser D: Cell migration in
the immune system: the evolving inter-related roles of adhesion
molecules and proteinases. Dev Immunol. 7:103–116. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Garton KJ, Gough PJ, Blobel CP, Murphy G,
Greaves DR, Dempsey PJ and Raines EW: Tumor necrosis
factor-alpha-converting enzyme (ADAM17) mediates the cleavage and
shedding of fractalkine (CX3CL1). J Biol Chem. 276:37993–38001.
2001.PubMed/NCBI
|
|
32
|
Tsou CL, Haskell CA and Charo IF: Tumor
necrosis factor-alpha-converting enzyme mediates the inducible
cleavage of fractalkine. J Biol Chem. 276:44622–44626. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Théret N, Musso O, L'Helgoualc'h A and
Clément B: Activation of matrix metalloproteinase-2 from hepatic
stellate cells requires interactions with hepatocytes. Am J Pathol.
150:51–58. 1997.PubMed/NCBI
|
|
34
|
Théret N, Lehti K, Musso O and Clément B:
MMP2 activation by collagen I and concanavalin A in cultured human
hepatic stellate cells. Hepatology. 30:462–468. 1999.PubMed/NCBI
|
|
35
|
Bourd-Boittin K, Basset L, Bonnier D,
L'Helgoualc'h A, Samson M and Théret N: CX3CL1/fractalkine shedding
by human hepatic stellate cells: contribution to chronic
inflammation in the liver. J Cell Mol Med. 13:1526–1535. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dean RA and Overall CM: Proteomics
discovery of metalloproteinase substrates in the cellular context
by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol
Cell Proteomics. 6:611–623. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Inoue A, Hasegawa H, Kohno M, Ito MR,
Terada M, Imai T, Yoshie O, Nose M and Fujita S: Antagonist of
fractalkine (CX3CL1) delays the initiation and ameliorates the
progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum.
52:1522–1533. 2005. View Article : Google Scholar : PubMed/NCBI
|
